---
title: 'Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management
  of peripheral neuropathy in a multisite cohort'
date: '2023-08-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37595053/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230819180950&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: In the non-trial setting, BV+AVD was associated with a
  high incidence of PN. In our cohort, which includes patients who would not have
  been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher
  than previously reported, but 2-year outcomes remain ...'
disable_comments: true
---
CONCLUSIONS: In the non-trial setting, BV+AVD was associated with a high incidence of PN. In our cohort, which includes patients who would not have been eligible for the pivotal ECHELON-1 trial, BV discontinuation rates were higher than previously reported, but 2-year outcomes remain ...